{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:28:56Z","timestamp":1791332936018,"version":"4.3.1"},"reference-count":177,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2010]]},"DOI":"10.3960\/jslrt.50.9","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T06:04:53Z","timestamp":1274853893000},"page":"9-25","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of Adult T-cell Leukemia"],"prefix":"10.3960","volume":"50","author":[{"given":"Kimiharu","family":"Uozumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.10.6476"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.8.2534"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H : Adult T-cell leukemia : Clinical and hematologic features of 16 cases. Blood 50 : 481-492, 1977","DOI":"10.1182\/blood.V50.3.481.bloodjournal503481"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2008.00465.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Miyata T, Yonekura K, Utsunomiya A, Kanekura T, Nakamura S, <I>et al<\/I>. : Cutaneous type adult T-cell leukemia\/lymphoma is a characteristic subtype and includes erythema\/papule and nodule\/tumor subgroups. Int J Cancer doi:10.1002\/ijc.24874","DOI":"10.1002\/ijc.24874"},{"key":"7","unstructured":"7 Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, <I>et al<\/I>. : Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma : a proposal from an international consensus meeting. J Clin Oncol 27 : 453-459, 2009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Tobinai K, Watanabe T : Adult T-cell leukemia-lymphoma. In : Abeloff MD, Armitage JO, Niederhuber JE, <I>et al<\/I>. (eds) Clinical Oncology, 4 th ed, Philadelphia, Elsevier Churchill Livingstone, pp. 2425-2441, 2008","DOI":"10.1016\/B978-0-443-06694-8.50118-4"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(91)90087-A"},{"key":"10","unstructured":"10 Takemori N, Hirai K, Onodera R, Saito N, Watanabe S, <I>et al<\/I>. : Splenectomy followed by local injections of interferon-alpha is effective for treating cutaneous-type adult T-cell leukemia\/lymphoma. Br J Dermatol 129 : 746-747, 1993"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.46.6319"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb06933.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Shimizu S, Yasui C, Koizumi K, Ikeda H, Tsuchiya K : Cutaneous-type adult T-cell leukemia\/lymphoma presenting as a solitary large skin nodule : a review of the literature. J Am Acad Dermatol 57 : S115-S117, 2007","DOI":"10.1016\/j.jaad.2006.12.031"},{"key":"14","unstructured":"14 Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de Th&eacute; H, <I>et al<\/I>. : New therapeutic approaches for adult T-cell leukemia. Lancet Oncol 5 : 664-672, 2004"},{"key":"15","unstructured":"15 Uozumi K, Arima N : Recent advances and future perspectives in the treatment of adult T-cell leukemia\/lymphoma (ATL\/L). Recent Res Devel Haematol 2 : 1-19, 2005"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.01016.x"},{"key":"17","unstructured":"17 Uozumi K, Hanada S, Ohno N, Ishitsuka K, Shimotakahara S, <I>et al<\/I>. : Combination chemotherapy (RCM protocol : response-oriented cyclic multidrug protocol) for the acute or lymphoma type adult T-cell leukemia. Leuk Lymphoma 18 : 317-323, 1995"},{"key":"18","unstructured":"18 Uozumi K, Nakahara K, Takatsuka Y, Ohno N, Makino T, <I>et al<\/I>. : Granulocyte colony-stimulating factor in the combination chemotherapy for adult T-cell leukemia (ATL). Leuk Lymphoma 29 : 407-414, 1998"},{"key":"19","unstructured":"19 Matsushita K, Matsumoto T, Ohtsubo H, Fujiwara H, Imamura N, <I>et al<\/I>. : Long-term maintenance combination chemotherapy with OPEC\/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia\/lymphoma. Leuk Lymphoma 36 : 67-75, 1999"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Hagemeister FB : Treatment of relapsed aggressive lymphomas : regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol 49 : S13-S20, 2002","DOI":"10.1007\/s00280-002-0447-1"},{"key":"21","unstructured":"21 Okamoto T, Nishimura Y, Yamada S, Yamada S, Itoh T, <I>et al<\/I>. : Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma. Acta Haematol 104 : 128-130, 2000"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931215)72:12<3614::AID-CNCR2820721211>3.0.CO;2-E"},{"key":"23","unstructured":"23 Kagami Y, Ariyoshi Y, Horiuchi A, Kanamaru A, Kano Y, <I>et al<\/I>. : Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group. Int J Hematol 64 : 221-229, 1996"},{"key":"24","unstructured":"24 Tobinai K : Chemotherapy of ATL. In : Sugamura K, Uchiyama T, Matsuoka M, Kannagi M. (eds.) : Two decades of adult T-cell leukemia and HTLV-I research. Basel, Karger, pp. 263-276, 2003"},{"issue":"7","key":"25","first-page":"1444","volume":"44","year":"1981","ISSN":"https:\/\/id.crossref.org\/issn\/0001-5806","issn-type":"print"},{"key":"26","unstructured":"26 Lymphoma Study Group : Final results of cooperative study of VEPA [vincristine, cyclophosphamide (Endoxan), prednisolone and adriamycin] therapy in advanced adult non-Hodgkin's lymphoma : relation between T- or B-cell phenotype and response. Jpn J Clin Oncol 12 : 227-238, 1982"},{"key":"27","unstructured":"27 Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, <I>et al<\/I>. : Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 6 : 128-141, 1988"},{"key":"28","unstructured":"28 Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, <I>et al<\/I>. : Major prognostic factors of adult patients with advanced T-cell lymphoma\/leukemia. J Clin Oncol 6 : 1088-1097, 1988"},{"key":"29","unstructured":"29 Tobinai K, Shimoyama M, Minato K, Shirakawa S, Hotta T, <I>et al<\/I>. : Japan Clinical Oncology Group phase II trial of second-generation &ldquo;LSG4 protocol&rdquo; in aggressive T- and B-lymphoma : a new predictive model for T- and B-lymphoma. Proc Am Soc Clin Oncol 13 : 378, 1994 (abstract)"},{"key":"30","unstructured":"30 Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, <I>et al<\/I>. : Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 77 : 164-170, 2003"},{"key":"31","unstructured":"31 Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, <I>et al<\/I>. : A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma : Japan Clinical Oncology Group Study 9303. Br J Haematol 113 : 375-382, 2001"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900115)65:2<327::AID-CNCR2820650224>3.0.CO;2-W"},{"key":"33","unstructured":"33 Kuwazuru Y, Hanada S, Furukawa T, Yoshimura A, Sumizawa T, <I>et al<\/I>. : Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 76 : 2065-2071, 1990"},{"key":"34","unstructured":"34 Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, <I>et al<\/I>. : VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25 : 5458-5464, 2007"},{"issue":"2","key":"35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00042560-199606010-00012","volume":"12","year":"1996","ISSN":"https:\/\/id.crossref.org\/issn\/1077-9450","issn-type":"print"},{"key":"36","unstructured":"36 Ohno N, Tani A, Uozumi K, Hanada S, Furukawa T, <I>et al<\/I>. : Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood 98 : 1160-1165, 2001"},{"key":"37","unstructured":"37 Ohno N, Tani A, Chen Z-S, Uozumi K, Hanada S, <I>et al<\/I>. : Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res 7 : 3120-3126, 2001"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8"},{"issue":"4","key":"39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bjc.1994.394","volume":"70","year":"1994","ISSN":"https:\/\/id.crossref.org\/issn\/0007-0920","issn-type":"print"},{"key":"40","unstructured":"40 Tsukasaki K, Maeda T, Arimura K, Taguchi J, Fukushima T, <I>et al<\/I>. : Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma : a case report and review of the literature. Bone Marrow Transplant 23 : 87-89, 1999"},{"key":"41","unstructured":"41 Nakane M, Ohashi K, Sato Y, Moriya A, Inoue T, <I>et al<\/I>. : Molecular remission in adult T cell leukemia after autologous CD 34<SUP>+<\/SUP> peripheral blood stem cell transplantation. Bone Marrow Transplant 24 : 219-221, 1999"},{"key":"42","unstructured":"42 Obama K, Tara M, Sao H, Taji H, Morishima Y, <I>et al<\/I>. : Allogenic bone marrow transplantation as a treatment for adult T-cell leukemia. Int J Hematol 69 : 203-205, 1999"},{"key":"43","unstructured":"43 Tajima K, Amakawa R, Uehira K, Matsumoto N, Shimizu T, <I>et al<\/I>. : Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Int J Hematol 71 : 290-293, 2000"},{"key":"44","unstructured":"44 Sobue R, Yamauchim T, Miyamura K, Sao H, Tahara T, <I>et al<\/I>. : Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. Bone Marrow Transplant 2 : 441-444, 1987"},{"key":"45","unstructured":"45 Borg A, Yin JA, Johnson PR, Tosswill J, Saunders M, <I>et al<\/I>. : Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Haematol 4 : 713-715, 1996"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702731"},{"key":"47","unstructured":"47 Kami M, Hamaki T, Miyakoshi S, Murashige N, Kanda Y, <I>et al<\/I>. : Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia\/lymphoma. Br J Haematol 120 : 304-309, 2003"},{"key":"48","unstructured":"48 Yonekura K, Utsunomiya A, Takatsuka Y, Takeuchi S, Tashiro Y, <I>et al<\/I>. : Graft-versus-adult T-cell leukemia\/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 41 : 1029-1035, 2008"},{"key":"49","unstructured":"49 Ogata M, Ogata Y, Imamura T, Ohtsuka E, Kikuchi H, <I>et al<\/I>. : Successful bone marrow transplantation from an unrelated donor in a patient with adult T cell leukemia. Bone Marrow Transplant 30 : 699-701, 2002"},{"key":"50","unstructured":"50 Abe Y, Yashiki S, Choi I, Hara K, Matsushima T, <I>et al<\/I>. : Eradication of virus-infected T-cells in a case of adult T-cell leukemia\/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. Int J Hematol 76 : 91-93, 2002"},{"key":"51","unstructured":"51 Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, <I>et al<\/I>. : Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma. Leukemia 19 : 829-834, 2005"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Nakase K, Hara M, Kozuka T, Tanimoto K, Nawa Y : Bone marrow transplantation from unrelated donors for patients with adult T-cell leukemia\/lymphoma. Bone Marrow Transplant 37 : 41-44, 2006","DOI":"10.1038\/sj.bmt.1705197"},{"key":"53","unstructured":"53 Kato K, Kanda Y, Eto T, Muta T, Gondo H, <I>et al<\/I>. : Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia\/lymphoma : Retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant 13 : 90-99, 2007"},{"key":"54","unstructured":"54 Hamaki T, Kami M, Igarashi M, Kusumi E, Arase Y, <I>et al<\/I>. : Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment. Leuk Lymphoma 44 : 703-708, 2003"},{"key":"55","unstructured":"55 Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, <I>et al<\/I>. : Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma. Blood 105 : 4143-4145, 2005"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Obama K, Utsunomiya A, Takatsuka Y, Takemoto Y : Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplant 34 : 897-899, 2004","DOI":"10.1038\/sj.bmt.1704692"},{"key":"57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-1452"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0754"},{"key":"59","unstructured":"59 Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, <I>et al<\/I>. : Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 14 : 583-590, 2008"},{"key":"60","unstructured":"60 Takizawa J, Aoki S, Kurasaki T, Higashimura M, Honma K, <I>et al<\/I>. : Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation. Am J Hematol 82 : 1113-1115, 2007"},{"key":"61","unstructured":"61 Fujiwara H, Kawada H, Matsushita K, Hamada H, Ozaki A, <I>et al<\/I>. : Case of a patient with progressive adult T-cell leukemia\/lymphoma treated successfully by reduced-intensity conditioning stem cell transplantation from an HLA-incompatible related donor. Int J Hematol 82 : 357-361, 2005"},{"key":"62","unstructured":"62 Fujiwara H, Ozaki A, Yoshimitsu M, Hamada H, Masamoto I, <I>et al<\/I>. : Allogeneic stem cell transplantation for refractory adult T-cell leukemia using a non-T-cell-depleted HLA-incompatible family donor graft, with reference to the grown-up child donor to parent recipient setting ; report of a pilot study. Int J Hematol 87 : 319-326, 2008"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Okamura J, Uike N, Utsunomiya A, Tanosaki R : Allogeneic stem cell transplantation for adult T-cell leukemia\/lymphoma. Int J Hematol 86 : 118-125, 2007","DOI":"10.1532\/IJH97.07070"},{"key":"64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506293322603"},{"key":"65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506293322604"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Tobinai K, Kobayashi Y, Shimoyama M : Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. Lymphoma Study Group of the Japan Clinical Oncology Group. N Engl J Med 333 : 1285, 1995","DOI":"10.1056\/NEJM199511093331911"},{"key":"67","unstructured":"67 Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, <I>et al<\/I>. : Interferon &alpha; and zidovudine therapy in adult T-cell leukaemia lymphoma : response and outcome in 15 patients. Br J Haematol 113 : 779-784, 2001"},{"key":"68","unstructured":"68 Hermine O, Allard I, Levy V, Arnulf B, Gessain A, <I>et al<\/I>. : A prospective phase II clinical trial with the use of zidovudine and interferon-&alpha; in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma. Hematol J 3 : 276-282, 2002"},{"key":"69","unstructured":"69 White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, <I>et al<\/I>. : The combination of zidovudine and interferon &alpha;-2b in the treatment of adult T-cell leukemia\/lymphoma. Leuk Lymphoma 40 : 287-294, 2001"},{"key":"70","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401742"},{"issue":"12","key":"71","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1128\/JVI.73.12.10289-10295.1999","volume":"73","author":"TAYLOR G P","year":"1999","ISSN":"https:\/\/id.crossref.org\/issn\/0022-538X","issn-type":"print"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Garcia-Lerma JG, Nidtha S, Heneine W : Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors : evidence for resistance to lamivudine. J Infect Dis 184 : 507-510, 2001","DOI":"10.1086\/322785"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Hill SA, Lloyd PA, McDonald S, Wykoff J, Derse D : Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J Infect Dis 188 : 424-427, 2003","DOI":"10.1086\/376531"},{"key":"74","unstructured":"74 Aouba A, Lambotte O, Vasiliu V, Divine M, Valensi F, <I>et al<\/I>. : Hemophagocytic syndrome as a presenting sign of transformation of smoldering to acute adult T-cell leukemia\/lymphoma : efficacy of anti-retroviral and interferon therapy. Am J Hematol 76 : 187-189, 2004"},{"key":"75","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01068.x"},{"key":"76","unstructured":"76 Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, <I>et al<\/I>. : Arsenic trioxide and interferon-&alpha; synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 93 : 278-283, 1999"},{"key":"77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3762"},{"key":"78","unstructured":"78 Ishitsuka K, Ikeda R, Utsunomiya A, Uozumi K, Hanada S, <I>et al<\/I>. : Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor-&alpha; receptor independent caspase activation. Leuk Lymphoma 43 : 1107-1114, 2002"},{"key":"79","unstructured":"79 Che XF, Zheng CL, Owatari S, Mutoh M, Gotanda T, <I>et al<\/I>. : Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood 107 : 4880-4887, 2006"},{"key":"80","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200374"},{"key":"81","unstructured":"81 Ishitsuka K, Suzumiya J, Aoki M, Ogata K, Hara S, <I>et al<\/I>. : Therapeutic potential of arsenic trioxide with or without interferon-\u03b1 for relapsed\/refractory adult T-cell leukemia\/lymphoma. Hematologica 92 : 719-720, 2007"},{"key":"82","unstructured":"82 Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, <I>et al<\/I>. : Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult Y-cell leukemia\/lymphoma (ATL). Blood 113 : 6528-6532, 2009"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Wang JC, Dick JE : Cancer stem cells : lessons from leukemia. Trends Cell Biol 15 : 494-501, 2005","DOI":"10.1016\/j.tcb.2005.07.004"},{"key":"84","doi-asserted-by":"publisher","DOI":"10.1038\/nature07016"},{"key":"85","unstructured":"85 Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, <I>et al<\/I>. : Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14 : 1333-1342, 2008"},{"key":"86","unstructured":"86 Yamazaki J, Mizukami T, Takizawa K, Kuramitsu M, Momose H, <I>et al<\/I>. : Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia\/lymphoma. Blood 114 : 2709-2720, 2009"},{"key":"87","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.35.180"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Miyatake JI, Maeda Y : Inhibition of proliferation and CD25 down-regulation by retinoic acid in human adult T cell leukemia cells. Leukemia 11 : 401-407, 1997","DOI":"10.1038\/sj.leu.2400593"},{"key":"89","unstructured":"89 Fujimura S, Suzumiya J, Anzai K, Ohkubo K, Hata T, <I>et al<\/I>. : Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res 22 : 611-618, 1998"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Nawata H, Maeda Y, Sumimoto Y, Miyatake J, Kanamaru A : A mechanism of apoptosis induced by all-trans retinoic acid on adult T-cell leukemia cells : a possible involvement of the Tax\/NF-&kappa;B signaling pathway. Leuk Res 25 : 323-231, 2001","DOI":"10.1016\/S0145-2126(00)00126-0"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Fujimura S, Suzumiya J, Yamada Y, Kuroki M, Ono J : Downregulation of Bcl-xL and activation of caspases during retinoic acid-induced apoptosis in an adult T-cell leukemia cell line. Hematol J 4 : 328-335, 2003","DOI":"10.1038\/sj.thj.6200321"},{"key":"92","unstructured":"92 Darwiche N, Hatoum A, Dbaibo G, Kadara H, Nasr R, <I>et al<\/I>. : N-(4-hydroxyphenyl) retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells. Leukemia 18 : 607-615, 2004"},{"key":"93","unstructured":"93 Toshima M, Nagai T, Izumi T, Tarumoto T, Takatoku M, <I>et al<\/I>. : All-trans-retinoic acid treatment for chemotherapy-resistant acute adult T-cell leukemia. Int J Hematol 72 : 343-345, 2000"},{"key":"94","unstructured":"94 Darwiche N, El-Sabban M, Bazzi R, Nasr R, Al-Hashimi S, <I>et al<\/I>. : Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor &alpha;-positive human T-cell lymphotropic virus type-I-transformed cells. Hematol J 2 : 127-135, 2001"},{"key":"95","unstructured":"95 Maeda Y, Yamaguchi T, Hijikata Y, Tanaka M, Hirase C, <I>et al<\/I>. : Clinical efficacy of all-trans retinoic acid for treating adult T-cell leukemia. J Cancer Res Clin Oncol 134 : 673-677, 2008"},{"key":"96","unstructured":"96 Okudaira T, Tomita M, Uchihara J, Matsuda T, Ishikawa C, <I>et al<\/I>. : NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-&kappa;B signal pathway. Mol Cancer Ther 5 : 704-712, 2006"},{"key":"97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00917.x"},{"key":"98","unstructured":"98 Arima N, Matsushita K, Obata H, Ohtsubo H, Fujiwara H, <I>et al<\/I>. : NF-&kappa;B involvement in the activation of primary adult T-cell leukemia cells and its clinical implications. Exp Hematol 27 : 1168-1175, 1999"},{"key":"99","unstructured":"99 Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, <I>et al<\/I>. : Constitutive activation of NF-&kappa;B in primary adult T-cell leukemia cells. Blood 93 : 2360-2368, 1999"},{"key":"100","unstructured":"100 Arima N, Tei C : HTLV-I Tax protein involved refractoriness of ATL : Molecular mechanisms and clinical significance. Recent Res Devel Haematol 1 : 103-115, 2003"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Horie R : NF-&kappa;B in pathogenesis and treatment of adult T-cell leukemia\/lymphoma. Int Rev Immunol 26 : 269-281, 2007","DOI":"10.1080\/08830180701703364"},{"key":"102","unstructured":"102 Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, <I>et al<\/I>. : Bay 11-7082 inhibits transcription factor NF-&kappa;B and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100 : 1828-1834, 2002"},{"key":"103","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.9.5286-5294.2003"},{"key":"104","unstructured":"104 Watanabe M, Ohsugi T, Shoda M, Ishida T, Aizawa S, <I>et al<\/I>. : Dual targeting of transformed and untransformed HTLV-1infected T cells by DHMEQ, a potent and selective inhibitor of NF-&kappa;B, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106 : 2462-2471, 2005"},{"key":"105","unstructured":"105 Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, <I>et al<\/I>. : <I>In vivo<\/I> antitumor activity of the NF-&kappa;B inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 26 : 1382-1388, 2005"},{"key":"106","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23860"},{"key":"107","unstructured":"107 Machijima Y, Ishikawa C, Sawada S, Okudaira T, Uchihara J, <I>et al<\/I>. : Anti-adult T-cell leukemia\/lymphoma effects of indole-3-carbinol. Retrovirology 6 : 7, 2009"},{"key":"108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"109","unstructured":"109 Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, <I>et al<\/I>. : Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both <I>in vivo<\/I> and <I>in vitro<\/I>. Leukemia 18 : 1357-1563, 2004"},{"key":"110","unstructured":"110 Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, <I>et al<\/I>. : Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia\/lymphoma. Oncogene 24 : 419-430, 2005"},{"key":"111","unstructured":"111 Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, <I>et al<\/I>. : Bortezomib therapy in patients with relapsed or refractory lymphoma : potential correlation of <I>in vitro<\/I> sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24 : 2105-2112, 2006"},{"key":"112","unstructured":"112 Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, <I>et al<\/I>. : The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis. Leukemia 23 : 1507-1514, 2009"},{"key":"113","unstructured":"113 Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, <I>et al<\/I>. : Depsipeptide (FR901228) : a novel therapeutic agent with selective, <I>in vitro<\/I> activity against human B-cell chronic lymphocytic leukemia cells. Blood 94 : 1401-1408, 1999"},{"key":"114","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2865"},{"key":"115","unstructured":"115 Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, <I>et al<\/I>. : Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8 : 718-728, 2002"},{"key":"116","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4582-4590.2004"},{"key":"117","unstructured":"117 Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, <I>et al<\/I>. : Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 : 5410-5417, 2009"},{"key":"118","unstructured":"118 Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, <I>et al<\/I>. : Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 : 3109-3115, 2007"},{"key":"119","unstructured":"119 Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, <I>et al<\/I>. : Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor &kappa;B. Leuk Res 32 : 287-296, 2008"},{"key":"120","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404902"},{"key":"121","unstructured":"121 O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, <I>et al<\/I>. : Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139 : 425-428, 2007"},{"key":"122","unstructured":"122 O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, <I>et al<\/I>. : Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27 : 4357-4364, 2009"},{"key":"123","unstructured":"123 Mameros AG, Grossman ME, Silvers DN, Husain S, Nuovo GJ, <I>et al<\/I>. : Pralatrevate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma\/leukemia causing skin erosions. Blood 113 : 6338-6341, 2009"},{"key":"124","unstructured":"124 Alonso R, Lopez-Guerra M, Upshaw R, Bantia S, Smal C, <I>et al<\/I>. : Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood 114 : 1563-1575, 2009"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125 Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V : Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 108 : 2392-2398, 2006","DOI":"10.1182\/blood-2006-03-007468"},{"key":"126","unstructured":"126 Gandhi V, Kilpatrick J, Plunkett W, Ayres M, Harman L, <I>et al<\/I>. : A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106 : 4253-4260, 2005"},{"key":"127","unstructured":"127 Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, <I>et al<\/I>. : Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 27 : 5404-5409, 2009"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128 Teachey DT, Grupp SA, Brown VI : Mammalian target of rapamycin inhibitors and their potential role in therapy in leukemia and other haematological malignancies. Br J Haematol 145 : 569-580, 2009","DOI":"10.1111\/j.1365-2141.2009.07657.x"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129 Robinson KS, Williams ME, Van der Jagt RH, Cohen P, Herst JA, <I>et al<\/I>. : Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26 : 4473-4479. 2008","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"130","unstructured":"130 Pro B, Leber B, Smith M, Fayad L, Romaguera J, <I>et al<\/I>. : Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143 : 355-360, 2008"},{"key":"131","unstructured":"131 Perez-Galan P, Roue G, Lopez-Guerra M, Nguyen M, Villamor N, <I>et al<\/I>. : BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 22 : 1712-1720, 2008"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132 Balakrishnan K, Wierda WG, Keating MJ, Gandhi V : Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112 : 1971-1980, 2008","DOI":"10.1182\/blood-2007-12-126946"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133 Balakrishnan K, Burger JA, Wierda WG, Gandhi V : AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113 : 149-153, 2009","DOI":"10.1182\/blood-2008-02-138560"},{"key":"134","unstructured":"134 Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, <I>et al<\/I>. : Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113 : 4403-4413, 2009"},{"key":"135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0144"},{"key":"136","unstructured":"136 Evens AM, Ziegler SL, Gupta R, Augustyniak C, Gordon LI, <I>et al<\/I>. : Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia\/lymphoma. Clin Lymphoma Myeloma 7 : 472-474, 2007"},{"issue":"11","key":"137","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1128\/JVI.66.11.6288-6293.1992","volume":"66","year":"1992","ISSN":"https:\/\/id.crossref.org\/issn\/0022-538X","issn-type":"print"},{"key":"138","unstructured":"138 Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, <I>et al<\/I>. : Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer : a p53-independent induction of p21WAF1\/CIP1 via C\/EBP&beta;. Nat Med 3 : 1233-1241, 1997"},{"key":"139","unstructured":"139 Arima N, Arimura K, Tokito Y, Sakaki Y, Matsushita K, <I>et al<\/I>. : HTLV-I Tax protein inhibits apoptosis induction but not G1 arrest by pyrrolidinedithiocarbamate, an anti-oxidant, in adult T cell leukemia cells. Exp Hematol 32 : 195-201, 2004"},{"key":"140","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-121913"},{"key":"141","unstructured":"141 Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, <I>et al<\/I>. : Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia 23 : 2090-2101, 2009"},{"key":"142","unstructured":"142 Ito S, Oyake T, Murai K, Ishida Y : Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells. Leuk Res doi : 10.1016\/j.leukres.2009.09.003"},{"key":"143","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00175.x"},{"key":"144","unstructured":"144 Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, <I>et al<\/I>. : Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma : its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9 : 3625-3634, 2003"},{"key":"145","unstructured":"145 Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, <I>et al<\/I>. : Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4<SUP>+<\/SUP>CD25<SUP>+<\/SUP> regulatory T cells. J Exp Med 194 : 847-853, 2001"},{"key":"146","unstructured":"146 Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, <I>et al<\/I>. : The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia\/lymphoma. Clin Cancer Res 10 : 7529-7539, 2004"},{"key":"147","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00307.x"},{"key":"148","unstructured":"148 Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, <I>et al<\/I>. : Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD\/Shi-<I>scid<\/I>, IL-2R&gamma;<SUP>null<\/SUP> mice <I>in vivo<\/I>. J Immunol 183 : 4782-4791, 2009"},{"key":"149","unstructured":"149 Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, <I>et al<\/I>. : Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD\/Shi-<I>scid<\/I>, IL-2R&gamma;<SUP>null<\/SUP> mouse model. Cancer Immunol Immunother 58 : 1195-1206, 2009"},{"key":"150","unstructured":"150 Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, <I>et al<\/I>. : Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28 : 1591-1598, 2010"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151 Waldmann TA : Multichain interleukin-2 receptor : a target for immunotherapy in lymphoma. J Natl Cancer Inst 81 : 914-923, 1989","DOI":"10.1093\/jnci\/81.12.914"},{"key":"152","unstructured":"152 Waldmann TA, White JD, Goldman CK, Top L, Grant A, <I>et al<\/I>. : The interleukin-2 receptor : a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82 : 1701-1712, 1993"},{"issue":"4","key":"153","first-page":"1059","volume":"54","year":"1994","ISSN":"https:\/\/id.crossref.org\/issn\/0008-5472","issn-type":"print"},{"key":"154","unstructured":"154 Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, <I>et al<\/I>. : Radioimmunotherapy of interleukin-2R&alpha;-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86 : 4063-4075, 1995"},{"key":"155","unstructured":"155 Ohno N, Kreitman RJ, Saito T, Masamoto I, Uozumi K, <I>et al<\/I>. : Augmentation of the activity of an immunotoxin, anti-Tac (Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I. Leuk Lymphoma 43 : 885-888, 2002"},{"key":"156","doi-asserted-by":"crossref","unstructured":"156 Zhang M, Zhang Z, Goldman CK, Janik J, Waldmann TA : Combination therapy for adult T-cell leukemia-xenografted mice : flavopiridol and anti-CD25 monoclonal antibody. Blood 105 : 1231-1236, 2005","DOI":"10.1182\/blood-2004-05-1709"},{"issue":"4","key":"157","first-page":"1083","volume":"62","author":"TAN C","year":"2002","ISSN":"https:\/\/id.crossref.org\/issn\/0008-5472","issn-type":"print"},{"key":"158","doi-asserted-by":"crossref","unstructured":"158 Chen J, Zhang M, Ju W, Waldmann TA : Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 113 : 1287-1293, 2009","DOI":"10.1182\/blood-2008-04-149658"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159 Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA : Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 102 : 284-288, 2003","DOI":"10.1182\/blood-2002-11-3601"},{"key":"160","unstructured":"160 Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA : Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 63 : 6453-6457, 2003"},{"key":"161","doi-asserted-by":"crossref","unstructured":"161 Dearden CE, Matutes E, Catovsky D : Alemtuzumab in T-cell malignancies. Med Oncol 19 : S27-S32, 2002","DOI":"10.1385\/MO:19:2S:S27"},{"key":"162","unstructured":"162 Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, <I>et al<\/I>. : Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27 : 5425-5430, 2009"},{"key":"163","unstructured":"163 Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, <I>et al<\/I>. : A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103 : 1838-1845, 2004"},{"key":"164","unstructured":"164 Callens C, Moura IC, Lepelletier Y, Coulon S, Renand A, <I>et al<\/I>. : Recent advances in adult T-cell leukemia therapy : focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 22 : 42-48, 2008"},{"key":"165","doi-asserted-by":"crossref","unstructured":"165 Maeda N, Muta H, Oflazoglu E, Yoshikai Y : Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies <I>in vitro<\/I> and <I>in vivo<\/I>. Cancer Sci doi:10.1111\/j.1349-7006.2009.01354.x","DOI":"10.1111\/j.1349-7006.2009.01354.x"},{"key":"166","unstructured":"166 Kchour G, Tarhini M, Sharifi N, Farid R, Khooei AR, <I>et al<\/I>. : Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma. Leuk Lymphoma 49 : 265-270, 2008"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167 Kchour G, Makhoul NJ, Mahmoudi M, Kooshyar MM, Shirdel A : Zidovudine and interferon-&alpha; treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk lymphoma 48 : 330-336, 2007","DOI":"10.1080\/10428190601071717"},{"key":"168","unstructured":"168 Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, <I>et al<\/I>. : Rituximab, bevacitumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma : safety, biomarker and pharmacokinetic analysis. Leuk lymphoma 47 : 998-1005, 2006"},{"key":"169","doi-asserted-by":"crossref","unstructured":"169 Kannagi M, Sugamura K, Kinoshita K, Uchino H, Hinuma Y : Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia\/lymphoma patient. J Immunol 133 : 1037-1041, 1984","DOI":"10.4049\/jimmunol.133.2.1037"},{"key":"170","doi-asserted-by":"publisher","DOI":"10.1038\/348245a0"},{"key":"171","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910540411"},{"key":"172","unstructured":"172 Hanabuchi S, Ohashi T, Koya Y, Kato H, Hasegawa A, <I>et al<\/I>. : Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model : peptide-induced T-cell immunity. J Natl Cancer Inst 93 : 1775-1783, 2001"},{"key":"173","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.20.9610-9616.2000"},{"key":"174","unstructured":"174 Kannagi M, Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, <I>et al<\/I>. : Adult T-cell leukemia : future prophylaxis and immunotherapy. Expert Rev Anticancer Ther 4 : 369-376, 2004"},{"key":"175","unstructured":"175 Sundaram R, Sun Y, Walker CM, Lemonnier FA, Jacobson S, <I>et al<\/I>. : A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A<SUP>*<\/SUP>0201 transgenic mice : implications for HTLV-1 vaccine design. Vaccine 21 : 2767-2781, 2003"},{"key":"176","unstructured":"176 Sundaram R, Lynch MP, Rawale S, Dakappagari N, Young D, <I>et al<\/I>. : Protective efficacy of multiepitope human leukocyte antigen-A<SUP>*<\/SUP>0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus. J Acquir Immune Defic Syndr 37 : 1329-1339, 2004"},{"key":"177","doi-asserted-by":"crossref","unstructured":"177 Kannagi M : Immunologic control of human T-cell leukemic virus type I and adult T-cell leukemia. Int J Hematol 86 : 113-117, 2007","DOI":"10.1532\/IJH97.07092"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T08:42:59Z","timestamp":1685608979000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jslrt\/50\/1\/50_1_9\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":177,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.50.9","relation":{},"ISSN":["1880-9952","1346-4280"],"issn-type":[{"value":"1880-9952","type":"electronic"},{"value":"1346-4280","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}